Mechanism

PCSK9 Inhibitors

treatment

comparator

All cause death (0)

Coronary death (1)

Coronary event (2)

Cardiovascular death (3)

stroke (fatal and non fatal) (4)

myocardial infarction (fatal and non fatal) (5)

cardiovascular events (6)

Allergic reactions (7)

serious adverse events (8)

death from all causes as adverse event (9)

cardiovascular events as adverse event (10)

Muscle-related adverse events (11)

Neurocognitive disorder (12)

neurological SAE (13)

myocardial infarction as adverse event (14)

cardiovascular death as adverse event (15)

unstable angina as adverse death (16)

Edit

Alirocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Alirocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Alirocumab

cardiovascular prevention, in all type of patients

-

-

-

-

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.85 [0.73 0.98]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,
Coronary death	0.92 [0.76 1.11]	p=1.00	0	18924	1	ODYSSEY OUTCOMES,
Coronary event	0.88 [0.80 0.96]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,
Cardiovascular death	0.88 [0.74 1.05]	p=1.00	0	18924	1	ODYSSEY OUTCOMES,
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
cardiovascular events	0.87 [0.81 0.94]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,
Allergic reactions	1.06 [0.79 1.41]	p=1.00	0	2341	1	ODYSSEY Long-Term,
serious adverse events	0.98 [0.82 1.18]	p=1.00	0	3732	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
death from all causes as adverse event	0.38 [0.15 0.96]	p=0.04	0	3735	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
cardiovascular events as adverse event	0.91 [0.61 1.36]	p=1.00	0	2341	1	ODYSSEY Long-Term,
Muscle-related adverse events	no data
Neurocognitive disorder	2.28 [0.77 6.77]	p=1.00	0	2341	1	ODYSSEY Long-Term,
neurological SAE	0.94 [0.62 1.43]	p=1.00	0	2341	1	ODYSSEY Long-Term,
myocardial infarction as adverse event	0.44 [0.22 0.85]	p=0.04	0	2908	3	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY COMBO,
cardiovascular death as adverse event	0.38 [0.18 0.77]	p=0.04	0	3735	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
unstable angina as adverse death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ODYSSEY Long-Term, 2015	alirocumab 150 mg as a 1-ml subcutaneous injection every 2 weeks for 78 weeks.	placebo	patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy
ODYSSEY Alternative,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Ezetimibe 10 mg	statin-intolerant patients
ODYSSEY OUTCOMES, 2018	Alirocumab (on top intensive or maximum-tolerated statin therapy)	placebo	Post-ACS patients (1 to 12 months)with elevated levels of atherogenic lipoproteins despite intensive or maximum-tolerated statin therapy
ODYSSEY FH 1,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY FH 2,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY HIGH FH ,	Alirocumab 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY COMBO,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	high cardiovascular risk patients on maximally tolerated statin therapy
ODYSSEY COMBO II,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Ezetimibe 10 mg	high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins

Evolocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Evolocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Evolocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Evolocumab

cardiovascular prevention, in all type of patients

-

-

-

-

-

-

-